Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

October 15, 2024 8:00 AM EDT

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12  17 years, broadening the population in which nipocalimab has been studied 

SAVANNAH, Ga., Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 17 years) living with generalized myasthenia gravis (gMG). Study participants who were treated with nipocalimab plus... More